Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C

Blood Cancer Journal

Volumn 6, Issue , 2016, Pages

  Lin, R J ^a   Moskovits, T ^a   Diefenbach, C S ^a   Hymes, K B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IBRUTINIB; INTERFERON; MYC PROTEIN; RIBAVIRIN; SOFOSBUVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ADULT; AGED; ANOREXIA; BONE MARROW BIOPSY; CASE REPORT; CELL PROLIFERATION; CHRONIC HEPATITIS C; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ERYTHEMA; HEPATOSPLENOMEGALY; HUMAN; HUMAN TISSUE; HYPERTENSION; LETTER; LIMB WEAKNESS; LIVER CIRRHOSIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; NIGHT SWEAT; SKIN BIOPSY; SPINAL CORD COMPRESSION; SPLENECTOMY; VIRAL CLEARANCE; VIRUS LOAD; WEIGHT REDUCTION; COMPLICATION; DISEASE COURSE; HEPATITIS C; LYMPHOMA, MANTLE-CELL; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84960854273     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2016.16     Document Type: Letter

References (13)

1. Vannata B, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2014; 2014: 590-598.
2. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 131: 1879-1886.
3. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-458.
4. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006; 15: 2078-2085.
5. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111: 1-8.
6. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-1798.
7. Hermine O, Lefrere F, Bronowicki J-P, Mariette X, Jondeau K, Eclache-Saudreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
8. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716.
9. Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 2015; 90: 197-203.
10. Levine AM, Shimodaira S, Lai MMC. Treatment of HCV-related mantle-cell lymphoma with Ribavirin and pegylated interferon alfa. N Engl J Med 2003; 349: 2078-2079.
11. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122: 3416-3423.
12. Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 2015; 122: 3416-3423.
13. Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) 2015; 7: 49-64.